Mallinckrodt pursues core quest with Questcor merger

Just nine months after spinning out from Covidien, Mallinckrodt is maintaining its ambition to grow its speciality pharma business aggressively with the planned $5.6bn merger with Questcor Pharmaceuticals. The announcement came only weeks after Mallinckrodt closed its $1.3bn acquisition of Cadence Pharmaceuticals (www.scripintelligence.com, 12 February 2014) and continues to fulfil the commitment Mark Trudeau, Mallinckrodt’s president and CEO, made to investors and analysts last fall.